Table 1 Summary patient and study characteristics influencing the NNT value in GLP-1 RA and SGLT-2i CVOTs
From: Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials
CVOT | Drug | Primary outcome | Annual placebo primary outcome rate (N/100 patient-year) | Median follow-up (years) | NNT (according to Altman & Andersen’s formula) with 95% CI |
|---|---|---|---|---|---|
GLP-1 RA | |||||
 LEADER [22] | Liraglutide | 3P-MACE | 3.9 | 3.8 | 56 [33–243] |
 SUSTAIN-6 [23] | Semaglutide | 3P-MACE | 4.4 | 2.1 | 45 [28–235] |
 HARMONY-Outcomes [24] | Albiglutide | 3P-MACE | 5.9 | 1.6 | 53 [36–116] |
 REWIND [25] | Dulaglutide | 3P-MACE | 2.7 | 5.1 | 67 [38–803] |
 EXSCEL [19] | Exenatide | 3P-MACE | 4.0 | 3.2 | Not significant |
 ELIXA [26] | Lixisenatide | 4P-MACE | 6.3 | 2.1 | Not significant |
 PIONEER-6 [27] | Semaglutide (oral) | 3P-MACE | 3.7 | 1.3 | Not significant |
SGLT-2i | |||||
 EMPAREG-Outcome [18] | Empagliflozin | 3P-MACE | 4.4 | 3.1 | 63 [34–882] |
 DECLARE-TIMI58 [28] | Dapagliflozin | CV death or hospitalization for heart failure | 1.5 | 4.2 | 104 [66–355] |
3P-MACE | 2.4 | 4.2 | Not significant | ||
 CANVAS [29] | Canagliflozin | 3P-MACE | 3.15 | 2.4 | Not calculable* |